|
|
Volumn 4, Issue 3, 2004, Pages 273-275
|
|
Development of novel therapeutics to treat joint diseases - What can be learned from other disease areas?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADIPONECTIN;
ADVANCED GLYCATION END PRODUCT;
ANALGESIC AGENT;
ANTIINFLAMMATORY AGENT;
ANTIRHEUMATIC AGENT;
CYCLOOXYGENASE 2 INHIBITOR;
CYTOKINE;
CYTOKINE ANTIBODY;
GLUCOSAMINE;
HYALURONIC ACID DERIVATIVE;
IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;
INSULIN;
INTERLEUKIN 1 ANTIBODY;
INTERLEUKIN 15 ANTIBODY;
INTERLEUKIN 17 ANTIBODY;
INTERLEUKIN 6;
INTERLEUKIN 6 ANTIBODY;
INTERMEDIN;
LEPTIN;
LIGAND;
MITOGEN ACTIVATED PROTEIN KINASE P38;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST;
RESISTIN;
SOMATOMEDIN C;
TUMOR NECROSIS FACTOR ALPHA;
TUMOR NECROSIS FACTOR ALPHA ANTIBODY;
UNCLASSIFIED DRUG;
ANALGESIA;
ANALGESIC ACTIVITY;
ANTIINFLAMMATORY ACTIVITY;
DISEASE ASSOCIATION;
DRUG COST;
DRUG HALF LIFE;
DRUG INDUSTRY;
DRUG MECHANISM;
EDITORIAL;
HUMAN;
INFECTION;
JOINT DESTRUCTION;
NON INSULIN DEPENDENT DIABETES MELLITUS;
OBESITY;
OSTEOARTHRITIS;
OSTEOPOROSIS;
PATHOLOGY;
PRIORITY JOURNAL;
PSORIASIS;
RHEUMATOID ARTHRITIS;
RISK FACTOR;
|
|
EID: 2342571612
PISSN: 14714892
EISSN: None
Source Type: Journal
DOI: 10.1016/j.coph.2004.04.002 Document Type: Editorial |
|
Times cited : (2)
|
|
References (0)
|
